Clinical Trial Update: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on combined atezolizumab and derazantinib for advanced intrahepatic cholangiocarcinoma with FGFR2 fusions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Derazantinib (derazantinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING